Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).

Literature DB >> 10952773

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).

M Nocera¹, E Baudin, G Pellegriti, A F Cailleux, C Mechelany-Corone, M Schlumberger.

Abstract

Combinations of doxorubicin and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 10 long-term stabilizations were observed. No unexpected toxicity occurred. Copyright 2000 Cancer Research Campaign.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2000 PMID： 10952773 PMCID： PMC2363532 DOI： 10.1054/bjoc.2000.1314

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

20 in total

1. Chemotherapy for thyroid cancer.

Authors: P J Hoskin; C Harmer
Journal: Radiother Oncol Date: 1987-11 Impact factor: 6.280

2. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors: J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal: Ann Surg Date: 1990-10 Impact factor: 12.969

Review 3. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia.

Authors: D D Chi; J F Moley
Journal: Surg Oncol Clin N Am Date: 1998-10 Impact factor: 3.495

4. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors.

Authors: J Frame; D Kelsen; N Kemeny; E Cheng; D Niedzwiecki; R Heelan; R Lippermann
Journal: Am J Clin Oncol Date: 1988-08 Impact factor: 2.339

5. Reporting results of cancer treatment.

Authors: A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal: Cancer Date: 1981-01-01 Impact factor: 6.860

6. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

Authors: K Shimaoka; D A Schoenfeld; W D DeWys; R H Creech; R DeConti
Journal: Cancer Date: 1985-11-01 Impact factor: 6.860

7. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil.

Authors: S R Petursson
Journal: Cancer Date: 1988-11-01 Impact factor: 6.860

8. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial.

Authors: S D Williams; R Birch; L H Einhorn
Journal: Cancer Treat Rep Date: 1986-03

9. External radiotherapy in thyroid cancers.

Authors: M Tubiana; E Haddad; M Schlumberger; C Hill; P Rougier; D Sarrazin
Journal: Cancer Date: 1985-05-01 Impact factor: 6.860

10. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy.

Authors: J P Droz; M Schlumberger; P Rougier; M Ghosn; P Gardet; C Parmentier
Journal: Tumori Date: 1990-10-31

22 in total

Review 1. Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature.

Authors: Andrea Conway; Andres Wiernik; Ajay Rawal; Cornelius Lam; Hector Mesa
Journal: Endocr Pathol Date: 2012-06 Impact factor: 3.943

Review 2. Management of hereditary medullary thyroid carcinoma.

Authors: Theodora Pappa; Maria Alevizaki
Journal: Endocrine Date: 2016-02-02 Impact factor: 3.633

Review 3. Medullary thyroid cancer: monitoring and therapy.

Authors: Douglas W Ball
Journal: Endocrinol Metab Clin North Am Date: 2007-09 Impact factor: 4.741

Review 4. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.

Authors: Pamela Jo Harris; Keith C Bible
Journal: Expert Opin Investig Drugs Date: 2011-10 Impact factor: 6.206

5. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

Authors: Keith C Bible; Vera J Suman; Julian R Molina; Robert C Smallridge; William J Maples; Michael E Menefee; Joseph Rubin; Nina Karlin; Kostandinos Sideras; John C Morris; Bryan McIver; Ian Hay; Vahab Fatourechi; Jill K Burton; Kevin P Webster; Carolyn Bieber; Anne M Traynor; Patrick J Flynn; Boon Cher Goh; Crescent R Isham; Pamela Harris; Charles Erlichman
Journal: J Clin Endocrinol Metab Date: 2014-02-25 Impact factor: 5.958